Market overview

Eicosanedioic acid (C20 diacid, CAS 505-57-7) is a long-chain dicarboxylic acid best known as the fatty-acid side chain attached to tirzepatide, Eli Lilly’s GLP-1/GIP drug sold as Mounjaro and Zepbound. It extends the drug’s half-life by binding albumin. Volumes are small, but GMP-grade supply is critical to one of the fastest-growing drugs ever.

The question this report answers
How much C20 diacid will tirzepatide and next-generation GLP-1 drugs need, and who is qualified to supply it?

Market Krystal preliminary estimate (2025)
No public value. Assuming 5-15 t of tirzepatide API a year and losses through synthesis, we estimate 1-5 t of pharma-grade diacid at USD 2,000-10,000/kg, or USD 2-50 mn; wide by design. Confidence grade C: no reliable published figure; range built from the stated assumptions and narrowed in the full report.

Market dynamics
– Demand: tirzepatide and other acylated peptides
– Supply: few GMP-qualified producers
– Price and margin: pharma-grade premium
– Regulation and substitution: patent and compounding rules

Key figures at a glance (third-party, cited)
– Lilly’s 2025 revenue was USD 65.2 bn (+45%); Q4 2025 sales were USD 7.41 bn for Mounjaro and USD 4.26 bn for Zepbound (Finviz, Feb 2026)
– Lilly guided 2026 revenue to USD 80-83 bn (Finviz, Feb 2026)

Recent developments among key stakeholders
– Feb 2026: Lilly reported 2025 revenue of USD 65.2 bn and guided 2026 to USD 80-83 bn, driven by tirzepatide (Finviz)

What this means for the market
Every increase in tirzepatide output lifts demand for qualified C20 diacid side-chain intermediates. Suppliers with GMP and Lilly qualification hold a strategic position.

How published estimates compare
No credible public market estimate exists for pharma-grade eicosanedioic acid. Market Krystal estimates demand from tirzepatide API output and side-chain stoichiometry.

Strategic scenarios to 2047
– Base: GLP-1 and related incretin drugs keep growing as indications widen (obesity, cardiovascular, sleep apnoea), lifting demand for side-chain building blocks.
– Constrained supply: GMP-qualified side-chain supply lags drug demand, giving qualified producers pricing power.
– Technology transition: oral small-molecule GLP-1 drugs and new peptides change which side chains are needed after 2035.
The swing factor for Eicosanedioic acid is tirzepatide volumes and oral GLP-1 substitution. Signposts: Lilly and Novo volume guidance, oral GLP-1 approvals, patent expiries, compounding rules.

What this report delivers
Annual volume (tonnes) and value (USD) for 2026-2035, segmented by grade: GMP pharmaceutical (side-chain building block), technical (polymers, lubricants); application: GLP-1 drug side chains, specialty polyamides and polyesters, lubricants; region: US, Europe, China, India. Each segment is backed by a producer capacity table, price benchmarks for 2020-2025 by grade and region, trade-flow analysis and a supplier risk map. Companies assessed include Eli Lilly (customer), Peptide CDMOs, Chinese and Indian side-chain intermediate makers, Cathay Biotech (long-chain diacids). The 2036-2047 outlook uses three explicit scenarios (base, constrained supply and technology transition) rather than a single extrapolated curve.

Who uses this report
GLP-1 supply-chain teams, peptide CDMOs, healthcare and life-science investors.

Why our approach is evidence-based
Most CAS-level market listings publish a single number with no audit trail, and we regularly find figures that contradict their own growth rates or exceed the size of the market they sit inside. Market Krystal works the other way round. We start from physical evidence: plant capacities, production and trade data, company disclosures, regulatory texts and price records. We build volume and price separately and only then compute value. Every third-party figure is cited, every Market Krystal estimate is labelled with its method and a confidence grade, and conflicts between sources are shown rather than hidden. Confidence grades: A = two or more independent sources agree, or government or company data; B = one published estimate checked against volumes or prices; C = no reliable published figure, so the range is built from stated assumptions and narrowed in the full report.

Methodology and delivery
Prepared by the Market Krystal Chemicals Research Team. Each report is built around the buyer’s question: after purchase, a short scope confirmation fixes the priority regions, companies and applications, and the report is delivered within 5-7 business days with the Excel model behind every estimate, so buyers can audit and change the assumptions.

The purchased delivery includes the PDF report, Excel datasets and customization around the buyer’s priority region, company set, application or commercial question.

What this research answers

The study connects production routes, named suppliers, applications, regional demand, trade, pricing drivers and commercial opportunities for this CAS number. Detailed estimates and company analysis remain inside the purchased report.